Russian state-backed nanotechnology fund RusNano and a group of investors are investing $93m in three US-based pharmaceutical companies specialising in the development of drugs targeting illnesses such as epilepsy.
Rusnano has partnered with US venture capital firm Domain Associates and other investors for the deals, which comprise investments in Marinus Pharmaceuticals, Lithera and Regado Biosciences.
Marinus is developing a drug for the treatment of epilepsy, while Lithera works on products for aesthetic medicine and ophthalmology and Regado is developing antithrombotic drugs.
All three businesses are portfolio companies of Domain, which teamed up with Rusnano in March with plans to invest about $760m in the US healthcare and pharmaceutical companies.
Rusnano hopes the joint venture will bring new drugs to the Russian market.
Copyright © 2012 AltAssets